Company Encyclopedia
View More
name
ZHAOKE OPHTH-B
06622.HK
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People’s Republic of China.
1.371 T
06622.HKMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking41/47
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-14.89%E
    • Profit Margin-787.13%E
    • Gross Margin53.58%B
  • Growth ScoreE
    • Revenue YoY-38.11%E
    • Net Profit YoY-22.76%D
    • Total Assets YoY-11.65%E
    • Net Assets YoY-14.52%E
  • Cash ScoreD
    • Cash Flow Margin-12.70%D
    • OCF YoY-38.11%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreA
    • Gearing Ratio17.53%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZHAOKE OPHTH has authorized the distribution and supply of an innovative drug for the treatment of presbyopia in Indonesia

    ZHAOKE OPHTH has signed a distribution and supply agreement with Indonesian pharmaceutical company PTFerron, authorizing it to commercialize the innovative drug BRIMOCHOL PF for the treatment of presbyopia in Indonesia. The agreement grants PTFerron exclusive rights, including import, promotion, and sales of the product. ZHAOKE will receive an upfront payment and may obtain additional payments based on specific achievements. In addition, the developer of BRIMOCHOL PF, Tenpoint, received acceptance of its new drug application from the U.S. FDA in June

    etnet·
    HK
    06622
    -2.52%
    etnet·
    HK
    06622
    -2.52%

    Zhaoke Ophthalmology Signs Distribution Agreement with PT Ferron for BRIMOCHOL PF in Indonesia

    Zhaoke Ophthalmology Limited has signed a distribution agreement with PT Ferron Par Pharmaceuticals for BRIMOCHOL™ PF in Indonesia. PT Ferron will have exclusive rights to import, promote, distribute, market, and sell the drug, which treats presbyopia. Zhaoke will receive an upfront payment and additional milestone payments based on specific achievements.

    Reuters·
    HK
    06622
    -2.52%
    Reuters·
    HK
    06622
    -2.52%

    ZHAOKE OPHTH's partners have submitted a new drug application for BRIMOCHOL PF to the South Korean Ministry of Food and Drug Safety

    ZHAOKE OPHTH has collaborated with Tenpoint Therapeutics, Ltd. to assist Kwangdong Pharmaceutical Co., Ltd. in submitting a New Drug Application (NDA) for BRIMOCHOL PF to the Korean Ministry of Food and Drug Safety. The drug is based on positive data from the Phase III trial "BRIO-I," which shows that the combination therapy is superior to the single component. The NDA submission for BRIMOCHOL PF in Korea coincides with the NDA under review in the United States, with an FDA PDUFA date expected on January 28, 2026. This drug is a preservative-free eye drop primarily used for the correction of presbyopia

    AASTOCKS·
    HK
    06622
    -2.52%
    AASTOCKS·
    HK
    06622
    -2.52%

    After a cumulative drop of 30% in stock price over two and a half months, is ZHAOKE OPHTH-B about to reach a new turning point of simultaneous increase in volume and price?

    ZHAOKE OPHTH-B's stock price has fallen by 30% over the past two and a half months, experiencing multiple small fluctuations. Despite the company's new drug application being approved, the market reaction has been tepid, and the stock price has failed to sustain an upward trend in the short term. The current PB valuation is 0.92 times, lower than the industry average, and future trends are of great concern

    Zhitong·
    HK
    06622
    -2.52%
    Zhitong·
    HK
    06622
    -2.52%

    Zhaoke Ophthalmology Grants 8 Million Share Options to Boost Talent Retention

    Zhaoke Ophthalmology Ltd. has granted 8 million share options to 97 employees and directors under its Post-IPO Share Option Scheme, effective September 5, 2025. This initiative aims to enhance talent retention and improve the company's remuneration package. The current analyst rating for Zhaoke Ophthalmology (HK:6622) is a Hold, with a price target of HK$3.50. The company focuses on the ophthalmology sector and is listed on the Hong Kong Stock Exchange, with a market cap of HK$2.13 billion.

    Tip Ranks·
    HK
    06622
    -2.52%
    Tip Ranks·
    HK
    06622
    -2.52%